Incyte shares rose Thursday after the drugmaker named Bill Meury its new CEO, effective immediately, to replace the retiring Hervé Hoppenot.

Incyte has hired veteran biotech executive Bill Meury to succeed Herve Hoppenot at the helm of the biopharmaceutical company.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront.

At its founding in 2019 by Blackstone Life Sciences and Novartis, Anthos gained the rights from Novartis to develop abelacimab, a drug targeting stroke prevention and blood clots in those with ...

Reuters reported in December 2023 that Blackstone was exploring the sale of Anthos. Abelacimab belongs to a novel class of drugs known as factor XI inhibitors, designed to replace established blood ...

Anthos, launched by Blackstone Life Sciences and Novartis in 2019, has been advancing abelacimab through clinical development under a licence from Novartis. Abelacimab is a fully human monoclonal ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

At its founding in 2019 by Blackstone Life Sciences and Novartis, Anthos gained the rights from Novartis to develop abelacimab, a drug targeting stroke prevention and blood clots in those with ...